Insights
Featured Carousel
- Monetizing Energy Tax Credits Is Clearly Tax-Free, Unless It’s Not
- Are the FTC and DOJ Losing Antitrust Battles but Gaining Ground?
- Practical Implications of New DOJ Criminal Self-Disclosure Policies
- What To Expect From the IRS’ $80 Billion Strategic Operating Plan
- The Informed Board – Spring 2023
Topics Panel Section
As SPAC Boom Subsides, Some De-SPACed Companies Seek Chapter 11 Protection
A number of businesses that went public by merging with SPACs have had difficulty raising additional capital. Some have chosen to seek Chapter 11 protection to restructure their debt and preserve themselves as going concerns.
AI and Patent Law: Balancing Innovation and Inventorship
A Federal Circuit holding that patents can only be issued to human inventors complicates efforts to protect the intellectual property of the growing number of companies relying on artificial intelligence to create innovative products.
A number of businesses that went public by merging with SPACs have had difficulty raising additional capital. Some have chosen to seek Chapter 11 protection to restructure their debt and preserve themselves as going concerns.
A Federal Circuit holding that patents can only be issued to human inventors complicates efforts to protect the intellectual property of the growing number of companies relying on artificial intelligence to create innovative products.
A fast-growing market has emerged from the need by corporations to dispose of so-called legacy liabilities using mechanisms beyond the conventional insurance policy.
Our third annual report on Hong Kong-listed biotech companies examines how the sector performed during the challenging conditions for capital markets globally over the past 12 months. Although aggregate listing and subsequent fundraising activity for biotech firms in Hong Kong decreased over the past year, Hong Kong continues to serve a thriving biotech ecosystem and is well positioned to attract further companies to list as global market conditions recover. The report provides a comprehensive overview of the market in its current state, examining key data points for biotech companies undertaking IPOs on the Stock Exchange of Hong Kong Limited (HKEX) in calendar year 2022 and analyzing the corporate governance practices of all 56 biotech companies listed on HKEX as of December 31, 2022.
New Market Emerges for Legacy Liability Dispositions
A fast-growing market has emerged from the need by corporations to dispose of so-called legacy liabilities using mechanisms beyond the conventional insurance policy.
2023 Report on Hong Kong-Listed Biotech Companies
Our third annual report on Hong Kong-listed biotech companies examines how the sector performed during the challenging conditions for capital markets globally over the past 12 months. Although aggregate listing and subsequent fundraising activity for biotech firms in Hong Kong decreased over the past year, Hong Kong continues to serve a thriving biotech ecosystem and is well positioned to attract further companies to list as global market conditions recover. The report provides a comprehensive overview of the market in its current state, examining key data points for biotech companies undertaking IPOs on the Stock Exchange of Hong Kong Limited (HKEX) in calendar year 2022 and analyzing the corporate governance practices of all 56 biotech companies listed on HKEX as of December 31, 2022.
